Voting and Early Death; White House’s $149 Wegovy Plan; An $800,000 Placebo?Voting and Early Death; White House’s $149 Wegovy Plan; An $800,000 Placebo?
(MedPage Today) — Note that some links may require registration or subscription. A Finnish study found that voters had a lower risk for all-cause death over 21 years of follow-up compared with non-voters. (Journal of Epidemiology & Community… (MedPage Today) — Note that some links may require registration or subscription. A Finnish study found Read More
White House nears deal to lower prices for weight loss drugs Wegovy and ZepboundWhite House nears deal to lower prices for weight loss drugs Wegovy and Zepbound
The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of their weight loss drugs, a person familiar with the plan said. The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of Read More
World’s Best-Selling Med; Cost-Effectiveness of GLP-1 Drugs; TED Drug Heads to FDAWorld’s Best-Selling Med; Cost-Effectiveness of GLP-1 Drugs; TED Drug Heads to FDA
(MedPage Today) — The GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro) surpassed the cancer immunotherapy drug pembrolizumab (Keytruda) as the world’s best-selling medicine. (STAT) An Institute for Clinical and Economic Review report concluded… (MedPage Today) — The GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro) surpassed the cancer immunotherapy drug pembrolizumab (Keytruda) as the world’s best-selling medicine. Read More
Adjuvant T-DXd Cuts Recurrence Risk in Early Breast CancerAdjuvant T-DXd Cuts Recurrence Risk in Early Breast Cancer
(MedPage Today) — Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast cancer, according to results…
STAT+: News you need to know about AI medical coding and GLP-1 microdosingSTAT+: News you need to know about AI medical coding and GLP-1 microdosing
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Telehealth companies Noom, Found, and Hims & Hers have all recently launched programs to prescribe “microdosed” GLP-1s. The companies say that in small doses Read More
New model forecasts 10-year heart risk after breast cancer treatmentNew model forecasts 10-year heart risk after breast cancer treatment
A multi-institution research team led by Georgetown University Medical Center has developed and validated a model estimating the 10-year risk of heart failure or cardiomyopathy after early-stage breast cancer treatment. Separating women into low, moderate, and high risk ranged from 1.7% in the lowest to 19.4% in the highest group.
STAT+: Pharmalittle: We’re reading about FDA disarray, microdosing GLP-1 weight loss drugs, and moreSTAT+: Pharmalittle: We’re reading about FDA disarray, microdosing GLP-1 weight loss drugs, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have cool breezes and clear blue skies greeting us today. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle for Read More
Searching ‘weight’ can bring up Ozempic in results. It’s a drug advertising loopholeSearching ‘weight’ can bring up Ozempic in results. It’s a drug advertising loophole
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there’s a lot more wiggle room when companies pay to sponsor online search results. There are strict rules about what drug companies can say in TV or print ads. But a new study shows Read More
STAT+: Microdosing aims to extend the lifespan of the GLP-1 compounding marketSTAT+: Microdosing aims to extend the lifespan of the GLP-1 compounding market
Noom, Found, and Hims & Hers have all launched programs to prescribe “microdosed” GLP-1s in the last three months, following in the footsteps of many smaller direct-to-consumer telehealth companies. Microdosing is getting a shot of promotion from Hollywood, too: Noom has promoted its program alongside a new celebrity spokesperson, actor Rebel Wilson, and TV host Read More
Bariatric Surgery May Cut Costs and Weight More Than GLP-1 DrugsBariatric Surgery May Cut Costs and Weight More Than GLP-1 Drugs
Despite growing prescription numbers and spending on glucagon-like peptide 1 (GLP-1) receptor agonists for obesity treatment, metabolic bariatric surgery may result in greater weight loss and lower costs, according to a recent study in JAMA Surgery. This comes as obesity experts have noticed decreased demand for the weight-loss surgery, which is often considered the “last Read More